US-based medical device company Mitralign has finished enrolling patients in the early feasibility study, Scout, to test its Trialign System for transcatheter repair of functional tricuspid regurgitation (FTR).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to Mitralign CEO Rick Geoffrion, the company has enrolled an initial group of fifteen people marking the initiation of the first US feasibility test to evaluate the transcathether device in treating patients suffering from tricuspid regurgitation.

NewYork-Presbyterian / Columbia University Medical Center Interventional Echocardiography director and Scout study principal investigator Rebecca Hahn said: “The clinical community is excited about the potential opportunity to provide a breakthrough non-surgical option for patients with tricuspid regurgitation.

“We know the number of people suffering with tricuspid regurgitation is much bigger than previously reported, and we are in the nascent stages of treating this large, unaddressed population.

“The Trialign System leaves behind a very small footprint, so we believe this device has the potential to be a front line solution for patients with functional TR.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"The Trialign System leaves behind a very small footprint, so we believe this device has the potential to be a front line solution for patients with functional TR."

The tricuspid valve is located between the right atrium and the right ventricle which opens to allow blood to be pumped from the right atrium in to the right ventricle.

The valve closes as soon as the blood makes its way through it so that it cannot pass back.

Tricuspid regurgitation (TR) occurs when the tricuspid valve cannot open and close properly, causing blood to flow backward into the right atrium.

TR can cause heart enlargement and heart failure if it is not treated.

Image: Echocardiography hinting at severe tricuspid regurgitation. Photo: courtesy of AMC Echolab via Wikipedia.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact